medigraphic.com
ISSN 0188-9796 (Print)

2007, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2007; 15 (1)

Erectile dysfunction and aging

Zúñiga GS

Language: Spanish
References: 16
Page: 32-36
PDF size: 100.22 Kb.


ABSTRACT

Erectile dysfunction treatment begins with clinic history and examination. The psycometric trials or interrogatory may evidence the psycopathologic substrate, and make the psycologic or psychiatric reference necessary. If endocrin disturb is suspected, we must begin a hormonal survey. When hyperprolactinemia or gonadothropin deficiency is found, appropriate diagnosis and treatment must be done. It must be taken into account that in aging, the changes of testosterone levels, estrogen and TeBG levels, among others, can influence in the erectile capacity. The suspicion of androgen deficiency moves to obtain testosterone levels. If levels are ‹ 300 ng/dL, must begin androgens therapy, if is not contraindicated. In the patients without psychological disorders, without suspicion of endocrin problem, and testosterone levels › 300 ng/dL, we can begin a farmacological test with phospodiesterasa inhibitors, if they aren’t contraindicated. When this is contraindicated or ineffective, another noninvasive treatment like vacuum erection devices, or intrauretral alprostadil can be tried. Finally, the intracavernous injection test or penile prostheses, are therapeutic options when there is not response to initial treatments.


REFERENCES

  1. National Institutes of Health Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83.

  2. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 1994; 7: 711.

  3. Hirshkowitz M, Moore CA, O’Connor S et al. Androgen and sleep-related erections. J Psychosom Res 1997; 42(6): 541.

  4. Karacan I, Salis PJ, Hirshkowitz M et al. Erectile dysfunction in hypertensive men: sleep-related erections, penile blood flow, and musculovascular events. J Urol 1989; 142: 56.

  5. Carani C, Scuteri A, Marrama R, Bancroft J. Brief report-the effects of testosterone administration and visual erotic stimuli on nocturnal penile tumescence in normal men. Horm Behav 1990; 24: 435.

  6. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991; 44: 671.

  7. Caretta N, Ferling A, Palego PF, Foresta C. Erectile dysfunction in aging men: testosterone role in therapeutic protocols. J Endocrinol Invest 2005; 28 (11 Suppl): 108-11.

  8. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979; 45: 955.

  9. Carani C, Granata AR, Bancroft J, Marrama P. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995; 20: 743.

  10. Shabsigh R, Rajfer J, Aversa A, Traish AM, Yassin A, Kalinchenko SY, Buvat J. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60(9): 1087-92.

  11. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91(11): 4335-4343.

  12. Skolnick AA, for Medical News & Perspectives. Guidelines for treating erectile dysfunction issued (American Urological Assn). JAMA 1997; 277: 7.

  13. Skakkebaek J, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double-blind controlled study. Clin Endocrinol (Oxf) 1981; 14: 49.

  14. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20): 1397.

  15. Tolra JR, Campana JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, Crossover Study to Establish Preference of Patients with Erectile Dysfunction after Taking the Three PDE-5 Inhibitors. J Sex Med 2006; 3(5): 901-909.

  16. Segraves RT, Bari M, Segraves K, Spirnak P. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol 1991; 145: 1174.




2020     |     www.medigraphic.com